Orchestra BioMed Presents AVIM Therapy Data for Hypertensive Heart Disease and Heart Failure
Event summary
- Orchestra BioMed presented data on AVIM Therapy at THT and CRT 2026 meetings, highlighting potential for treating hypertensive heart disease and heart failure.
- Dr. David E. Kandzari presented pilot study data showing sustained systolic blood pressure reductions and improvements in cardiac hemodynamics and diastolic function.
- Dr. Dan Burkhoff summarized clinical evidence demonstrating long-term systolic blood pressure reductions and stable outcomes in pacemaker-indicated patients with hypertension.
The big picture
Orchestra BioMed's AVIM Therapy represents a novel approach to treating hypertensive heart disease and heart failure, leveraging existing pacemaker technology. The therapy addresses significant unmet needs in populations with limited therapeutic options, particularly those with heart failure with preserved ejection fraction (HFpEF). The strategic collaboration with Medtronic underscores the potential for commercial scalability in a multi-billion-dollar global market.
What we're watching
- Clinical Validation
- How the pilot study data will translate into outcomes in the ongoing BACKBEAT global pivotal study.
- Regulatory Pathway
- Whether AVIM Therapy can secure FDA approval based on the current clinical evidence and Breakthrough Device Designation.
- Commercial Potential
- The pace at which Orchestra BioMed can partner with Medtronic to bring AVIM Therapy to market for uncontrolled hypertension in pacemaker-indicated patients.